



# HepaSpheres™

## Microspheres

## Bibliography

- Amer T, El-khalek AMA, Sheha G. (2015). Intra-arterial chemoembolization with HepaSpheres 50-100µm for patients with unresectable hepatocellular carcinoma: initial experience in Egyptian liver hospital. *Egypt J Radiol & Nuc Med*, Dec;46(4):957-965. <https://www.sciencedirect.com/science/article/pii/S0378603X15001187>
- Bilbao JI, de Luis E, García de Jalón JA, et al. (2008). Comparative study of four different spherical embolic particles in an animal model; a morphologic and histologic evaluation. *J Vasc Interv Radiol*, Nov;19(11):1625-38. <https://www.ncbi.nlm.nih.gov/pubmed/18823795>
- Bishay VL, Maglione K, Khanna R, et al. (2014). Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy. *J Hepatocellular Carcinoma*, Nov 27; 1:187-193. <https://www.ncbi.nlm.nih.gov/pubmed/27508187>
- Bonne L, Verslype C, Laenen A, et al. (2017). Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results. *Radiol Oncol*, Mar 1;51(1): 74-80. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330173>
- Bryant M, Dom D, Zarzour J, et al. (2014). Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. *HPB (Oxford)*, Apr;16(4):327-35. <https://www.ncbi.nlm.nih.gov/pubmed/23980917>
- Cavalcante RN, Nasser F, Motta-Leal-Filho JM, et al. (2017). Occurrence of Vascular Lake Phenomenon as a Predictor of Improved Tumor Response in HCC Patients that Underwent DEB-TACE. *Cardiovasc Intervent Radiol*, Jul;40(7):1044-1051. <https://www.ncbi.nlm.nih.gov/pubmed/28500458>
- Dekervel J, Malenstein H, Vandecaveye V, et al. (2014). Transcatheter arterial chemoembolization with doxorubicin eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm followup. *J Vasc Intervent Radiol*, Feb;25(2):248-55. <https://www.ncbi.nlm.nih.gov/pubmed/24295569>
- de Luis E, Bilbao JI, de Círculos JA, et al. (2008). In vivo evaluation of a new embolic spherical particle (HepaSpheres) in a kidney animal model. *Cardiovasc Intervent Radiol*, Mar-Apr;31(2):367-76. <https://www.ncbi.nlm.nih.gov/pubmed/18167024>
- Du YQ, Hori S, Zhou WZ, et al. (2009). Embolization of high flow arteriovenous malformations with HepaSpheres microspheres. *Zhonghua Zheng Xing Wai Ke Za Zhi*, May;25(3):193-6. [Article in Chinese] <https://www.ncbi.nlm.nih.gov/pubmed/19803201>
- Duan F, EQ Wang, MGEH Lam, et al. (2016). Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC Beads, QuadraSpheres, and conventional ethiodized oil emulsion. *Radiol*, Feb;278(2):612-621. <https://www.ncbi.nlm.nih.gov/pubmed/26334787>
- Farghaly AMA, EhabFawzy AM, Seif HMA, et al. (2017) Doxorubicin-eluting beads versus combined conventional transarterial chemoembolization and percutaneous alcohol injection in the treatment of large hepatocellular carcinoma. *J Curr Med Res Pract*, May-August 2:105-110. [http://www.jcmrp.org.net/temp/JCurrMedResPract22105-5486751\\_151427.pdf](http://www.jcmrp.org.net/temp/JCurrMedResPract22105-5486751_151427.pdf)
- Gadaleta CD, Ranieri G. (2011). Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. *Crit Rev Oncol Hematol*, Oct;80(1):40-53. <https://www.ncbi.nlm.nih.gov/pubmed/21067940>
- Gadaleta CD, Solbiati L, Mattioli V, et al. (2013). Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients. *Radiol*, May;267(2):627-37. <https://www.ncbi.nlm.nih.gov/pubmed/23249572>
- Ginsburg M, Zivin S, Wroblewski K, et al. (2015). Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. *J Vasc Interv Radiol*, Mar;26(3): 330-341. <https://www.ncbi.nlm.nih.gov/pubmed/25534635>
- Grosso M, Vignali C, Quaretti P, et al. (2008). Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres; preliminary results from an Italian multicentre study. *Cardiovasc Intervent Radiol*, Nov-Dec;31(6):1141-9. <https://www.ncbi.nlm.nih.gov/pubmed/18696150>
- Guiu B, Deschamps F, Aho S, et al. (2012). Liver/biliary injuries following chemoembolization of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. *J Hepatol*, Mar;56:609-617. <https://www.ncbi.nlm.nih.gov/pubmed/22027582>
- Gupta S, Wright KC, Ensor J, et al. (2011). Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. *Cardiovasc Intervent Radiol*, Oct;34(5):1021-30. <https://www.ncbi.nlm.nih.gov/pubmed/21479746>
- Hidaka K, Nakamura M, Osuga K, et al. (2010). Elastic characteristics of microspherical embolic agents used for vascular interventional Radiology. *J Mech Behav Biomed Mater*, Oct;3(7):497-503. <https://www.ncbi.nlm.nih.gov/pubmed/20696414>
- Hiraki T, Koizumi J, Arai Y, et al. (2015). Transcatheter arterial embolization of hypervascular tumors with HepaSpheres: prospective multicenter open label clinical trial of microspheres in Japan. *Jpn J Radiol*, Aug;33(8):479-486. <https://www.ncbi.nlm.nih.gov/pubmed/26111877>
- Huppert P, Wenzel T, Wietholtz H. (2014). Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. *Cardiovasc Intervent Radiol*, Feb;37(1):154-64. <https://www.ncbi.nlm.nih.gov/pubmed/23670568>
- Idilman I, Peynircioglu B, Cil BE, et al. (2013). Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience. *Turk J Gastroenterol*, 24(2): 141-147. <https://www.ncbi.nlm.nih.gov/pubmed/23934461>
- Imai Y, Hirooka M, Koizumi Y, et al. (2016). Histological assessment of the efficacy of drug-eluting beads in portal tumor thrombosis of hepatocellular carcinoma. *Radiol Case Reports*, Dec 27;12(1):179-184. <https://www.ncbi.nlm.nih.gov/pubmed/28228906>
- Iwase K, Higaki J, Hyung-Eun Y, et al. (2002). Splenic artery embolization using contour emboli before laparoscopic or laparoscopic assisted splenectomy. *Surg Laparosc Endosc Percutan Tech*, Oct;12(5):331-336. <https://www.ncbi.nlm.nih.gov/pubmed/12409699>
- Jarzabek M, Jargietto T, Wolski A, et al. (2011). Drug-eluting microspheres transarterial chemoembolization (DEM TACE) in patients with liver metastases. Pilot study. *Pol J Radiol*, Jul; 76(3):26-32. <https://www.ncbi.nlm.nih.gov/pubmed/22802838>
- Jiaqi Y, Hori S, Minamitani K, et al. (1996). A new embolic material: super absorbent polymer (SAP) microsphere and its embolic effects. *Nippon Igaku Hoshasen Gakkai Zasshi*, Jan;56(1):19-24. [Article in Japanese] <https://www.ncbi.nlm.nih.gov/pubmed/8857094>
- Jordan O, Denys A, De Baere T, et al. (2010). Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC Bead and HepaSpheres loaded with doxorubicin and irinotecan. *J Vasc Interv Radiol*, Jul;21(7):1084-90. <https://www.ncbi.nlm.nih.gov/pubmed/20610183>
- Kamal MWH, Farshidpour M, Long AW, et al. (2014). Hepatocellular carcinoma with intra-atrial extension responding to transarterial chemoembolization via the right hepatic and right inferior phrenic arteries. *Gastrointest Cancer Res*, May;7(3-4): 111-6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171979>
- Kennoki N, Hori S, Yuki T, et al. (2017). Transcatheter arterial chemoembolization with spherical embolic agent in patients with pulmonary or mediastinal metastases from breast cancer. *J Vasc Interv Radiol*, Oct;28(10):1386-1394. <https://www.ncbi.nlm.nih.gov/pubmed/28728935>
- Kennoki N, Hori S, Yuki T, et al. (2015). [Transcatheter Arterial Chemoembolization with Super absorbent Polymer Microspheres for Large Lung Cystic Adenocarcinoma in the Left Pulmonary Cavity]. *Gan To Kagaku Ryoho*, Nov;42(11):1407-10. [Article in Japanese] <https://www.ncbi.nlm.nih.gov/pubmed/26602400>
- Khankan AA, Osuga K, Hori S, et al. (2004). Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol. *Radiat Med*, Nov-Dec;22(6):384-90. <https://www.ncbi.nlm.nih.gov/pubmed/15648453>
- Klass D, Owen D, Buczkowski A, et al. (2014). The effect of doxorubicin loading on response and toxicity with drug eluting embolization in resectable hepatoma: A dose escalation study. *Anticancer Res*, Jul; 34(7):3597-606. <https://www.ncbi.nlm.nih.gov/pubmed/24982375>
- Kos S, Wasan E, Weir G, et al. (2011). Elution characteristics of doxorubicin-loaded microspheres differ by drug-loading method and microsphere size. *J Vasc Interv Radiol*, Mar;22(3):361-8. <https://www.ncbi.nlm.nih.gov/pubmed/21353988>
- Kucukay F, Badem S, Karan A, et al. (2015). A single-center retrospective comparison of doxorubicin-loaded HepaSpheres transarterial chemoembolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. *J Vasc Intervent Radiol*, Nov; 26(11):1622-1629. <https://www.ncbi.nlm.nih.gov/pubmed/26321015>
- Lee KH, Liapi E, Cornell C, et al. (2010). Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. *Cardiovasc Intervent Radiol*, Jun;33(3):576-82. <https://www.ncbi.nlm.nih.gov/pubmed/20087738>
- Liu DM, Kos S, Buczkowski A, et al. (2012). Optimization of doxorubicin loading for superabsorbent polymer microspheres: in vitro analysis. *Cardiovasc Intervent Radiol*, Apr;35(2):391-8. <https://www.ncbi.nlm.nih.gov/pubmed/21567274>

36. Lu W, Jin X. L., Yang C., et al. (2017) Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial. *Cancer Biol Ther*, June3;18(6): 433-438. <https://www.ncbi.nlm.nih.gov/pubmed/28548587>
37. Maeda N, Osuga K, Shimazu K, et al. (2012). In vivo evaluation of cisplatin-loaded superabsorbent polymer microspheres for use in chemoembolization of VX2 liver tumors. *J Vasc Interv Radiol*, Mar;23:397-404. <https://www.ncbi.nlm.nih.gov/pubmed/22209264>
38. Maeda N, Osuga K, Higashihara H, et al. (2010). In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization. *J Vasc Interv Radiol*, Jun;21(6):877-81. <https://www.ncbi.nlm.nih.gov/pubmed/20417118>
39. Mansour MG, Ali SA. (2016). Transarterial chemoembolization using drug eluting microspheres in refractory colorectal liver metastases with 18F-FDG PET/CT follow-up to assess therapeutic response. *Egypt J Radiol Nuc Med*, Dec; 47:1467-1472. <https://www.sciencedirect.com/science/article/pii/S0378603X16301814>
40. Morimoto M, Kobayashi S, Moriya S, et al. (2017). Short-term efficacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization. *Abdom Radiol*, May; 42(5):1618. <https://www.ncbi.nlm.nih.gov/pubmed/27909772>
41. Osuga K, Maeda N, Higashihara H, et al. (2012). Current status of embolic agents for liver tumor embolization. *Int J Clin Oncol*, Aug;17(4):306-15. <https://www.ncbi.nlm.nih.gov/pubmed/22806426>
42. Osuga K, Hori S, Hiraishi K, et al. (2008). Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. *Cardiovasc Intervent Radiol*, Nov-Dec;31(6):1108-16. <https://www.ncbi.nlm.nih.gov/pubmed/18543028>
43. Osuga K, Hori S, Kitayoshi H, et al. (2002). Embolization of high flow arteriovenous malformations: experience with use of superabsorbent polymer microspheres. *J Vasc Interv Radiol*, Nov;13(11):1125-33. <https://www.ncbi.nlm.nih.gov/pubmed/12427812>
44. Osuga K, Khankan AA, Hori S, et al. (2002). Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. *J Vasc Interv Radiol*, Sep;13(9 Pt 1):929-34. <https://www.ncbi.nlm.nih.gov/pubmed/12354828>
45. Osuga K, Murakami T, Nakamura H, et al. (2001). A new embolic material: SAP-microsphere. *Nippon Rinsho*, Oct;59 Suppl 6:534-8. [Article in Japanese]. No abstract available. <https://www.ncbi.nlm.nih.gov/pubmed/11762007>
46. Pascale F, Fazel Afshin, Namur J. (2017). Laparoscopic subperitoneal injection of chemo-loaded particles lowers tumor growth on a rabbit model of peritoneal carcinomatosis. *Tumour Biology*, May;39(5):1010428317698381. <http://journals.sagepub.com/doi/10.1177/1010428317698381>
47. Poggi G, Quaretti P, Minoia C, et al. (2008). Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. *Anticancer Res*, Nov-Dec;28(6B):3835-42. <https://www.ncbi.nlm.nih.gov/pubmed/19192637>
48. Poggi G, Quaretti P, Minoia C, et al. (2008). Oxaliplatin-eluting microspheres for the treatment of intrahepatic cholangiocarcinoma: a case report. *Anticancer Res*, Sep-Oct;28(5B):2987-90. <https://www.ncbi.nlm.nih.gov/pubmed/19031944>
49. Prasad BPK, Ray B. (2016). Agitated saline sonography: a simple technique for intra-procedural feeder identification during transcatheter arterial chemoembolization of hepatocellular carcinoma. *Diagn Interv Radiol*, May-Jun; 22(3):269-272. <https://www.ncbi.nlm.nih.gov/pubmed/27015444>
50. Ranieri G, Asabella AN, Altini C, et al. (2016). A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. *OncoTargets Ther*, Dec 12;9:7527-7535. <https://www.ncbi.nlm.nih.gov/pubmed/28003766>
51. Rathmann N, Kara K, Budjan J, et al. (2017). Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization. *Anticancer Research*, Oct;37(10):5681-5685. <http://ar.iiarjournals.org/content/37/10/5681.figures-only>
52. Seki A, Shimono C. (2017). Transarterial chemoembolization for management of hemoptysis: initial experience in advanced primary liver cancer patients. *Jpn J Radiol*, March;35:495-504. <https://www.ncbi.nlm.nih.gov/pubmed/28608003>
53. Seki A, Hori S, Shimono C, et al. (2015). Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. *Jpn J Radiol*, Dec; 33(12):741-748. <https://www.ncbi.nlm.nih.gov/pubmed/26493810>
54. Seki A, Hori S. (2012.) Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting Microspheres for unresectable hepatocellular carcinoma. *Cardiovasc Intervent Radiol*, Jun;35(2):555-62. <https://www.ncbi.nlm.nih.gov/pubmed/21562932>
55. Seki A, Hori S, Kobayashi K, Narumiya S. (2011). Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. *Cardiovasc Intervent Radiol*, Jun;34(3):557-65. <https://www.ncbi.nlm.nih.gov/pubmed/20821211>
56. Sottani C, Poggi G, Melchiorre F, et al. (2013). Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE. *J Chromatogr B Analyt Technol Biomed Life Sci*, Feb; 915-916:71-78. <https://www.ncbi.nlm.nih.gov/pubmed/23337906>
57. Sottani C, Poggi G, Quaretti P, et al. (2012). Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. *Anticancer Res*, May;32(5):1769-74. <https://www.ncbi.nlm.nih.gov/pubmed/22593459>
58. Sottani C, Leoni E, Porro B, et al. (2009). Validation of an LC-MS/MS method for the determination of epirubicin in human serum of patients undergoing drug eluting microsphere-transarterial chemoembolization (DEM-TACE). *J Chromatogr B Analyt Technol Biomed Life Sci*, Nov 1; 877(29):3543-8. <https://www.ncbi.nlm.nih.gov/pubmed/19783235>
59. Sun JH, Zhou GH, Zhang YL, et al. (2017) Chemoembolization of liver cancer with drug-loading microsphere 50-100µm. *Oncotarget*, Jan 17;8(3):5392-5399. <https://www.ncbi.nlm.nih.gov/pubmed/28036272>
60. Thornton LM, Cabrera R., Kapp M, et al. (2017). Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chemolization for the Treatment of Hepatocellular Carcinoma. *Curr Probl Diagn Radiol*, Nov-Dec;46(6):402-409. <https://www.ncbi.nlm.nih.gov/pubmed/28392205>
61. van Malenstein H, Maleux G, Vandecaveye V, et al. (2011). A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. *Onkologie*, Jul;34:368-376. <https://www.ncbi.nlm.nih.gov/pubmed/21734423>
62. Vasanani R, Ginsurg M, Ahmed O, et al. (2016). Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplant. *Hepatobiliary Surg Nutr*, Jun;5(3):225-33. <https://www.ncbi.nlm.nih.gov/pubmed/27275464>
63. Yousef MI, Refaat MM, Faheem MH. (2017). Role of diffusion-weighted magnetic resonance imaging in the evaluation of hepatocellular carcinoma response to transcatheter arterial chemoembolization using drug eluting beads: correlation with dynamic MRI. *The Egyptian Journal of Radiology and Nuclear Medicine*, Volume 48, Number 4, pp. 817-824. <https://www.sciencedirect.com/science/article/pii/S0378603X17301134>
64. Zeng JY, Piao XH, Zou ZY, et al. (2018). Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis. *Oncotarget*, Jan;9(7):7557-7566. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800924/>
65. Zurstrassen CE, Girelli LPO, Tyng CJ, et al. (2017). Safety and efficacy of HepaSphere 50-100 µm in the treatment of hepatocellular carcinoma. *Minim Invasive Ther Allied Technol*, Aug;26(4):212-219. <https://www.ncbi.nlm.nih.gov/pubmed/28635404>

## REGULATORY INFORMATION


HepaSphere Microspheres are indicated for use in embolization of blood vessels with or without delivery of doxorubicin HCl for therapeutic or preoperative purposes in the following procedures:

- Embolization of hepatocellular carcinoma
- Embolization of metastases to the liver

HepaSphere Microspheres loaded with irinotecan are indicated for use in:

- Embolization of metastatic colorectal cancer (mCRC) to the liver

HepaSphere Microspheres are not sold in the United States.



**Before using refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.**



Understand. Innovate. Deliver.™

[merit.com](http://merit.com)

Merit Medical Systems, Inc.  
1600 West Merit Parkway  
South Jordan, Utah 84095  
1.801.253.1600  
1.800.35.MERIT

Merit Medical Europe, Middle  
East, & Africa (EMEA)  
Amerikalaan 42, 6199 AE  
Maastricht-Airport  
The Netherlands  
+31 43 358 82 22

Merit Medical Ireland Ltd.  
Parkmore Business Park West  
Galway, Ireland  
+353 (0) 91 703 733